Karyopharm Therapeutics (KPTI) Equity Ratio (2016 - 2025)
Karyopharm Therapeutics' Equity Ratio history spans 14 years, with the latest figure at 2.7 for Q4 2025.
- For Q4 2025, Equity Ratio fell 138.81% year-over-year to 2.7; the TTM value through Dec 2025 reached 2.7, down 138.81%, while the annual FY2025 figure was 2.7, 138.81% down from the prior year.
- Equity Ratio reached 2.7 in Q4 2025 per KPTI's latest filing, up from 2.8 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.05 in Q4 2022 to a low of 2.8 in Q3 2025.
- Average Equity Ratio over 5 years is 0.84, with a median of 0.53 recorded in 2021.
- Peak YoY movement for Equity Ratio: surged 82.18% in 2022, then tumbled 1118.19% in 2023.
- A 5-year view of Equity Ratio shows it stood at 0.26 in 2021, then soared by 82.18% to 0.05 in 2022, then crashed by 1118.19% to 0.57 in 2023, then plummeted by 99.71% to 1.13 in 2024, then plummeted by 138.81% to 2.7 in 2025.
- Per Business Quant, the three most recent readings for KPTI's Equity Ratio are 2.7 (Q4 2025), 2.8 (Q3 2025), and 2.28 (Q2 2025).